Market Signal Briefing

Partner offers

The Block may may earn a commission if you use our partner offers, at no extra cost to you.

Quick Take
World Liberty said it froze some user accounts in September following third-party security lapses and is beginning to reallocate funds to secure wallets.
Earlier this week, Sens. Elizabeth Warren and Jack Reed reportedly asked the Justice and Treasury Departments to investigate alleged WLF token sales to sanctioned entities, citing Accountable.US research.
World Liberty Financial, facing congressional scrutiny over alleged token sales to entities in sanctioned regions including North Korea, Russia, and Iran, said Wednesday it is working to "reallocate user funds and verified users' identity via KYC checks" following potential breaches.

In an X post, the Trump-connected project said that a "relatively small subset of user wallets were compromised via phishing attacks or exposed seed phrases" due to "third-party security lapses." The project is now testing new smart contract logic to safeguard these accounts.

"Users who submitted tickets and satisfied the required checks will have funds reallocated to new, secure wallets," World Liberty wrote. "In September, we froze impacted wallets and verified ownership to ensure a smooth transition."

It is unclear how many users were affected or the total amount of funds at risk. World Liberty noted that the issue "was not a WLFI platform or smart contract issue."

“Even with issues stemming from external vulnerabilities, the team prioritized the security of its users while meeting regulatory requirements,” World Liberty added. 

Sanctioned sales?Earlier this week, Senators Elizabeth Warren, D-Mass, and Jack Reed, D-R.I., called upon the Departments of Justice and Treasury to investigate alleged WLF token sales to sanctioned entities, citing a September report from Accountable.US, according to CNBC on Tuesday.

The “suspicious” transactions reportedly involved North Korean hacking group Lazarus, a sanctioned Russian “ruble-backed sanctions evasion tool,” and an Iranian crypto exchange, the watchdog claimed.

It is unclear whether World Liberty’s announcement on Wednesday is connected to Warren and Reed’s letter. This is not the first time that World Liberty — which names Eric Trump, Donald Trump Jr., and Barron Trump as co-founders — has raised concerns among congressmembers, who have raised concerns of potential conflicts of interest.

Of note, several blockchain security experts, including Taylor Moynahan, security lead at Ethereum's largest wallet, MetaMask, and Nick Bax, founder of Ump.eth, challenged some of the onchain analysis performed by Accountable that purportedly connected an address to Lazarus.

"TL/DR: someone wrote 14 pages about Lazarus based on a funky shitcoin token transfer," Bax wrote. "The worst part of this all (other than my Senator disseminating disinfo), is Shryder wasn't just falsely accused of being a DPRK hacker; it appears his big bag WLFI tokens (~$95k) got frozen as a result of this false positive."

Disclaimer: The Block is an independent media outlet that delivers news, research, and data. As of November 2023, Foresight Ventures is a majority investor of The Block. Foresight Ventures invests in other companies in the crypto space. Crypto exchange Bitget is an anchor LP for Foresight Ventures. The Block continues to operate independently to deliver objective, impactful, and timely information about the crypto industry. Here are our current financial disclosures.

© 2025 The Block. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

TAGS

AUTHOR Daniel Kuhn is a Senior Journalist and Editor at The Block, where he covers the crypto industry with a particular focus on tech. He previously served as deputy managing editor of opinion/features at CoinDesk. He first appeared in print in Financial Planning, a trade publication magazine. Before journalism, he studied philosophy as an undergrad, English literature in graduate school and business and economic reporting at an NYU professional program. You can connect with him on Twitter and Telegram @danielgkuhn or find him on Urbit as ~dorrys-lonreb. See More

WHO WE ARE The Block is a news provider that strives to be the first and final word on digital assets news, research, and data. +
Follow us on Google News

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the payment on November 18, 2025 of its first ever dividend – a special cash dividend of C$0.15 per common share – reflecting the Company's strong financial performance and continued success in accelerating the adoption of its unique, patented, life-saving and life-improving medical technologies. This special dividend.

Key Takeaways
An energy technology firm got a boost from an overseas sale, and a chip giant's shares rose ahead of its highly anticipated earnings report on Wednesday, Nov. 19, 2025.Shares of GE Vernova powered higher after the company signed its first wind repower agreement outside the U.S.Regulators in Connecticut voted to block Eversource Energy's sale of its water subsidiary, and shares of the utility company dropped.

Major U.S. equities indexes ticked higher Wednesday, with Nvidia (NVDA) rising 2.9% to lead chip stocks higher ahead of the AI darling's highly anticipated quarterly results after the bell.

The S&P 500 rose 0.4%, while the Dow Jones Industrial Average inched up 0.1% and the Nasdaq advanced 0.6%. See here for Investopedia's full daily market summary. 

Shares of GE Vernova (GEV), the energy technology company spun off from GE in April 2024, surged 7.3% after the company announced its first wind repower upgrade agreement outside the U.S. Under the deal, GE Vernova will provide 25 wind repower upgrade kits, used to modernize and extend the operational life of aging wind turbines, to Taiwan Power Company.

Constellation Energy (CEG) shares jumped 5.3% after the Department of Energy said it had provided a $1 billion loan to fund the utility company's plan to restart a decommissioned nuclear reactor at the Pennsylvania site formerly known as Three Mile Island. Constellation entered a deal last year with Microsoft (MSFT) to resume operations at the nuclear facility to help power the software giant's energy-intensive data centers.

Lowe’s Companies (LOW) reported better-than-expected adjusted profit for the third quarter, and shares of the home improvement retailer climbed 4%. The company highlighted an increase in online sales, strength in its business with professional contractors, and growth in "home services," a program that connects customers with licensed professionals for help with installation and remodeling projects. The strong report from Lowe's came a day after rival Home Depot (HD) missed quarterly earnings forecasts and cut its outlook, citing headwinds related to economic uncertainty and the housing market.

Shares of Google parent Alphabet (GOOGL, GOOG) gained 2.8% to close at an all-time high after the tech giant launched Gemini 3, its latest artificial intelligence model. Several analysts praised the newest version, saying it competes with state-of-the-art models from competitors like OpenAI and Anthropic. Wednesday's move into record territory followed gains earlier in the week after Warren Buffett's Berkshire Hathaway (BRK.A, BRK.B) disclosed a stake in Alphabet.

Eversource Energy (ES) stock dropped 12.5%, losing the most of any stock in the S&P 500, after regulators in Connecticut rejected the utility company's proposed sale of its Aquarion Water subsidiary to a newly created quasi-public entity for $2.4 billion. The state's Public Utilities Regulatory Authority voted unanimously to block the transaction, determining that it failed to meet the proper standards for managerial sustainability.

A pair of agricultural giants came under pressure following reports that the Trump administration may delay proposed cuts to incentives for biofuel imports. Shares of Archer-Daniels-Midland (ADM) and Bunge (BG), which process commodities like corn and soybeans into biofuel, slipped 3.8% and 3.1%, respectively.

Do you have a news tip for Investopedia reporters? Please email us at

[email protected]

NORTHBROOK, Ill.--(BUSINESS WIRE)--UL Solutions Inc. (NYSE: ULS), a global leader in applied safety science, today announced that it is expanding its global electromagnetic and wireless testing footprint with the development of a new laboratory in Germany that will test and certify large, high-power industrial equipment and appliances, and medical, consumer and automotive products. The laboratory will be strategically located on UL Solutions' existing campus, a UL Solutions Center of Excellence.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Western Alliance Bancorporation (NYSE: WAL) resulting from allegations that Western Alliance Bancorporation may have issued materially misleading business information to the investing public.

So what: If you purchased Western Alliance Bancorporation securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=46349 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On October 16, 2025, Western Alliance Bancorporation disclosed that it had initiated a lawsuit against a borrower, Cantor Group V LLC, alleging fraud related to collateral loans.

On this news, Western Alliance Bancorporation's stock fell 10.88% on October 16, 2025.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Skanska AB (publ) (OTCPK:SKBSY) Skanska AB (publ) - Analyst/Investor Day November 18, 2025 11:00 AM EST

Company Participants

Antonia Junelind - Senior Vice President of Investor Relations
Richard Kennedy - Executive Vice President
Anders Danielsson - President & CEO
Stale Rod - Executive Vice President
Claes Larsson - Executive Vice President
Lena Hok - Executive VP of Sustainability & Innovation
Jonas Rickberg - Executive VP & CFO

Conference Call Participants

Keivan Shirvanpour - SEB, Research Division
Graham Hunt - Jefferies LLC, Research Division
Stefan Erik Andersson - Danske Bank A/S, Research Division
Erik Granström - DNB Carnegie, Research Division
Nicolas Mora - Morgan Stanley, Research Division

Presentation

Antonia Junelind
Senior Vice President of Investor Relations

A warm welcome to Skanska's Capital Markets Day 2025, and a warm welcome to Seattle indeed. This fantastic office tower is the result of bringing our strong capabilities in project development together with our strong capabilities in construction. And the result, the quality that you see here is the quality that you see in all our buildings and infrastructure projects, and that is what our customers chooses us for. I'm Antonia Junelind. I'm the Senior Vice President for Skanska's Investor Relations, and I'm very happy to see so many of you here in the U.S. This is a very important market for us, and our operations here have grown significantly over the past few years, now representing a construction order backlog of more than NOK 150 billion and NOK 20 billion worth of investment in properties.

So today, we will provide you with a firsthand view of our operations here in the U.S. You will get a chance to meet the top management team and learn more about our market, the context that we're operating in and our capabilities here. You will also get the chance to tour this building along with 2 very interesting construction sites, namely the

Recommended For You

Elior Group SA (OTCPK:ELORY) Q4 2025 Earnings Call November 19, 2025 12:30 PM EST

Company Participants

Daniel Derichebourg - Chairman & CEO
Didier Grandpre - Group Chief Financial Officer

Conference Call Participants

Jaafar Mestari - BNP Paribas, Research Division
Pravin Gondhale - Barclays Bank PLC, Research Division
Sabrina Blanc - Sanford C. Bernstein & Co., LLC., Research Division
Christian Devismes - CIC Market Solutions, Research Division

Presentation

Operator

Welcome to the Elior Group Full Year 2024-'25 Financial Results Presentation. Please note, this call is being recorded. The management discussion and slide presentation plus the analyst question-and-answer session is broadcasted live over the Internet. Today's call will start with an introduction of Daniel Derichebourg, Chairman and Group CEO. Mr. Derichebourg will speak in French with an English translation right afterwards. After this introduction, Didier Grandpre, Group CFO, will carry on with the usual presentation before opening the Q&A session. Mr. Derichebourg, please go ahead.

Daniel Derichebourg
Chairman & CEO

[Interpreted] So hello, everybody. Firstly, I'm sorry for not speaking English, but you know what, at my age, I'm not going to start learning now. We had told you in May that everything was going a lot better. And if everything went according to plan, we would be able to pay out a dividend. And as you've seen in the press release, that has now been confirmed.

Okay. So I'd like to thank you all for being here. It really is an honor to have you all here. And I'd now like to hand over to our Financial Director, Didier Grandpre, who's going to take us through the results.

Didier Grandpre
Group Chief Financial Officer

Thank you, Daniel. Good afternoon, ladies and gentlemen, and welcome to Elior Group's full year results presentation. We have provided detailed financial information in our press release issued earlier this afternoon, which is available on

Recommended For You

FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, “TWVC”), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the “Cayman Litigation”). The Cayman Litigation involved claims by two minority shareholders relating to the requested redemption of preferred shares of the Company before the consummation of the Company’s merger with Maxpro Capital Acquisition Corporation in 2023.

The Settlement Agreement fully resolves all disputes between the Company and TWVC. Under the Agreement, the Company has agreed to pay TWVC a total of US$5 million in cash, to be made in several installments over a period of two years, plus approximately US$879,757.78 in associated legal expenses. As agreed in the Settlement Agreement, TWVC will withdraw all claims against the Company and its affiliates, and the parties are in the process of submitting the Settlement and Settlement Agreement for the court’s approval to conclude the associated litigation proceedings. The original amount of damages claimed by TWVC was approximately US$40 million, as disclosed in the Form 20-F filed in April 2025.

About Apollomics Inc.
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries. For more information, please visit www.apollomicsinc.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib, or future proceedings with respect to the Cayman Litigation, are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2024, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law.

DALLAS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The Board of Trustees of the Texas Capital Funds Trust (the “Board”) has authorized an orderly liquidation of the Texas Capital Texas Small Cap Equity Index ETF (NASDAQ: TXSS) (the “Fund”). After careful consideration of the Fund’s size, asset composition and growth trajectory, the Board determined that it is advisable and in the best interest of the Fund and its shareholders to liquidate the Fund. As constructed, TXSS shared some of the portfolio constituents and other attributes of its larger counterpart, the Texas Capital Texas Equity Index ETF (NYSE: TXS). Our investors can continue to benefit from the growth of the Texas economy by investing in TXS.

The last day of trading for the Fund’s shares on NASDAQ will be December 8, 2025 (the “Closing Date”). On that date, the Fund will stop accepting creation units from authorized participants. Shareholders may sell their holdings through their brokerage accounts prior to the Closing Date. The Fund is expected to cease operations, liquidate its assets, and distribute the liquidation proceeds to shareholders on December 15, 2025 ("Liquidation Date"). Between the Closing Date and the Liquidation Date, shareholders may only be able to sell their shares to certain broker-dealers and there is no assurance that a market for the Fund’s shares will be available during this period.

Shareholders who continue to hold shares through the Liquidation Date will receive a cash distribution based on the net asset value (“NAV”) of their holdings as of that date, which will include any accumulated capital gains and dividends. The liquidation and related distributions may be treated as a taxable event. Shareholders should consult their tax advisers regarding the potential tax implications of the liquidation. Following completion of the distributions, the Fund will be formally closed and terminated.

About Texas Capital Bancshares, Inc.
Texas Capital Bancshares, Inc. (NASDAQ®: TCBI), a member of the Russell 2000® Index and the S&P MidCap 400®, is the parent company of Texas Capital Bank (“TCB”). Texas Capital is the collective brand name for TCB and its separate, non-bank affiliates and wholly-owned subsidiaries. Texas Capital is a full-service financial services firm that delivers customized solutions to businesses, entrepreneurs and individual customers. Founded in 1998, the institution is headquartered in Dallas with offices in Austin, Houston, San Antonio and Fort Worth, and has clients across the country.

Texas Capital services clients across their entire lifecycle providing commercial, consumer, private and full capital markets capabilities. All services are subject to applicable laws, regulations, and service terms. Deposit and lending products and services are offered by TCB. For deposit products, member FDIC. For more information, please visit www.texascapital.com.

Texas Capital Bank Wealth Management Services, Inc. d/b/a Texas Capital Bank Private Wealth Advisors (“PWA”), a wholly owned subsidiary of Texas Capital Bank and a Registered Investment Advisor with the U.S. Securities and Exchange Commission (“SEC”), serves as investment adviser to the Fund and is paid a fee for its services.

Shares of the Texas Capital Texas Small Cap Equity Index ETF are not deposits or obligations of, or guaranteed or endorsed by, Texas Capital Bank or its affiliates. The Texas Capital Texas Small Cap Equity Index ETF is not insured by the FDIC or any other government agency. The Texas Capital Texas Small Cap Equity Index ETF is distributed by Northern Lights Distributors, LLC, member FINRA/SIPC, which is not affiliated with Texas Capital Bank Private Wealth Advisors.

Investing involves risk, including loss of principal. Investment return and principal value of an investment will fluctuate, and an investor’s shares, when redeemed, may be worth more or less than their original value.

Investors should carefully consider the investment objectives, risks, and charges of the Funds before investing. The prospectus contains this information and other information about the Funds, and it should be read carefully before investing. Investors can obtain a copy of the prospectus by calling 844.TCB.ETFS(844.822.3837)

, /PRNewswire/ -- The Board of Directors of Quaker Houghton (NYSE: KWR) today declared a quarterly cash dividend of $0.508 per share, payable on January 30, 2026, to shareholders of record at the close of business on January 16, 2026.

About Quaker Houghton

Quaker Houghton is the global leader in industrial process fluids. With a presence around the world, including operations in over 25 countries, our customers include thousands of the world's most advanced and specialized steel, aluminum, automotive, aerospace, offshore, container, mining, and metalworking companies. Our high-performing, innovative and sustainable solutions are backed by best-in-class technology, deep process knowledge and customized services. With approximately 4,400 employees, including chemists, engineers and industry experts, we partner with our customers to improve their operations so they can run even more efficiently, even more effectively, whatever comes next. Quaker Houghton is headquartered in Conshohocken, Pennsylvania, located near Philadelphia in the United States. Visit quakerhoughton.com to learn more.

SOURCE Quaker Houghton

Also from this source

Resources

Investor Relations

Journalists

Agencies

Client Login

Send a Release

News

Products

Contact

, /PRNewswire/ -- Richmond Mutual Bancorporation, Inc. (NASDAQ: RMBI) announced today that its Board of Directors has declared a cash dividend on Richmond Mutual Bancorporation common stock of $0.15 per share. The cash dividend will be payable on December 18, 2025, to stockholders of record as of the close of business on December 4, 2025.

About Richmond Mutual Bancorporation, Inc.

Richmond Mutual Bancorporation, Inc., headquartered in Richmond, Indiana, is the holding company for First Bank Richmond, a community-oriented financial institution offering traditional financial and trust services within its local communities through its eight locations in Richmond, Centerville, Cambridge City and Shelbyville, Indiana, its five locations in Sidney, Piqua and Troy, Ohio and its loan production office in Columbus, Ohio.

SOURCE Richmond Mutual Bancorporation, Inc.

Also from this source

Resources

Investor Relations

Journalists

Agencies

Client Login

Send a Release

News

Products

Contact

, /PRNewswire/ -- FMC Corporation (NYSE: FMC) today announced that Pierre Brondeau, chairman and chief executive officer, and Andrew Sandifer, executive vice president and chief financial officer, will speak at the Goldman Sachs Industrials and Materials Conference on December 3, 2025, at 1:30 p.m. Eastern Time.  A live webcast will be available at www.fmc.com/investors.

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn®.

SOURCE FMC Corporation

Also from this source

Total revenue of $723.6 million for the first nine months of 2025 versus $222.3 million for the first nine months of 2024, an increase of 225.5%
Net income attributable to Nutex Health Inc. of $59.0 million for the first nine months of 2025 versus net loss of $9.5 million for the first nine months of 2024, an increase of $68.5 million
Diluted income per share of $8.87 for the first nine months of 2025 versus a loss per share of $1.91 for the first nine months of 2024
EBITDA of $142.9 million for the first nine months of 2025 versus $19.9 million for the first nine months of 2024, an increase of 616.4%
Adjusted EBITDA of $243.0 million for the first nine months of 2025 versus $16.1 million for the first half nine months of 2024, an increase of 1408.6%
Net cash from operating activities of $177.7 million for the first nine months of 2025

, /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), today announced financial results for the three and nine months ended September 30, 2025. Nutex Health is a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks.

Financial highlights for the three months ended September 30, 2025:

Total revenue increased $189.0 million to $267.8 million for the three months ended September 30, 2025 as compared to total revenue of $78.8 million for the same period in 2024, an increase of 239.9%. The hospital division drove most of this growth, generating $260.2 million, up 262.8% from $71.7 million for the third quarter of 2024. Revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 208.9% in 2025 compared to 2024.
Of the $260.2 million in hospital revenue, $182.1 million (or approximately 70.0%) related to a combination of both higher acuity claims as well as success through the Independent Dispute Resolution (IDR) process.
With regard to arbitration-related revenue: due to the continual underpayment from payors, we have continued to submit between 60-70% of our visits through the IDR process, we have won a legal determination on over 85% of the claims submitted, and we currently have an average collection rate of over 80% of the legal determination wins.
Arbitration costs approximate 24-26% of the arbitration related revenue.
Total stock-based compensation expense for the three months ended September 30, 2025 was $13.2 million compared to $2.0 million for the same period in 2024. Approximately 99.5% of total stock-based compensation expense of $13.2 million is due to the one-time obligations for under-construction and ramping hospitals.
Operating income for the three months ended September 30, 2025 was $130.4 million compared to $9.7 million for the same period in 2024, representing a $120.7 million improvement year over year.
Net income attributable to Nutex Health for the three months ended September 30, 2025 of $55.4 million as compared to net loss attributable to Nutex Health of $8.8 million for the same period in 2024. The $55.4 million in net income includes non-cash stock-based compensation expense of $13.2 million, while the $8.8 million net loss includes non-cash stock-based compensation expense of $2.0 million.
EBITDA attributable to Nutex Health of $91.8 million, as compared to EBITDA attributable to Nutex Health of $4.3 million for the three months ended September 30, 2024, an increase of 2014.0%.
Adjusted EBITDA attributable to Nutex Health of $98.5 million, as compared to Adjusted EBITDA attributable to Nutex Health of $9.7 million for the three months ended September 30, 2024.
Total visits at the Hospital Division were 46,232 for the three months ended September 30, 2025, as compared to 41,668 for the same period in 2024, an increase of 4,564 or 11.0%. Visits at mature hospitals decreased by 0.6% in the three months ended September 30, 2025 as compared to the same period in 2024.
Net cash from operating activities of $99.5 million for the three months ended September 30, 2025.
As of September 30, 2025, the Company had total assets of $964.5 million, including cash and cash equivalents of $166.0 million, and long-term debt, net of $25.6 million.

Financial highlights for the nine months ended September 30, 2025:

Total revenue increased $501.2 million to $723.6 million for the nine months ended September 30, 2025 as compared to total revenue of $222.3 million for the same period in 2024, an increase of 225.5%. The hospital division drove most of this growth, generating $700.5 million, up 251.4% from $199.4 million for the first nine months of 2024. Revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 200.0% in 2025 compared to 2024.
Of the $700.5 million in hospital revenue, $462.9 million (or approximately 66.1%) related to a combination of both higher acuity claims as well as success through the IDR process.
With regard to arbitration-related revenue: due to the continual underpayment from payors, we have continued to submit between 60-70% of our visits through the IDR process, we have won a legal determination on over 85% of the claims submitted, and we currently have an average collection rate of over 80% of the legal determination wins.
Arbitration costs approximate 24-26% of the arbitration related revenue.
Total stock-based compensation expense for the nine months ended September 30, 2025 was $119.6 million compared to $2.0 million for the same period in 2024. Approximately 99.5% of total stock-based compensation expense of $119.6 million is due to the one-time obligations for under-construction and ramping hospitals.
Operating income for the nine months ended September 30, 2025 was $244.7 million compared to $16.4 million for the same period in 2024, representing a $228.3 million improvement year over year.
Net income attributable to Nutex Health for the nine months ended September 30, 2025 of $59.0 million as compared to net loss attributable to Nutex Health of $9.5 million for the same period in 2024. The $59.0 million in net income includes non-cash stock-based compensation expense of $119.6 million, while the $9.5 million net loss includes non-cash stock-based compensation expense of $2.0 million.
EBITDA attributable to Nutex Health of $142.9 million, as compared to EBITDA attributable to Nutex Health of $19.9 million for the nine months ended September 30, 2024, an increase of 616.4%.
Adjusted EBITDA attributable to Nutex Health of $243.0 million, as compared to Adjusted EBITDA attributable to Nutex Health of $16.1 million for the nine months ended September 30, 2024.
Total visits at the Hospital Division were 140,074 for the nine months ended September 30, 2025, as compared to 122,944 for the same period in 2024, an increase of 17,130 or 13.9%. Visits at mature hospitals increased by 1.8% in the nine months ended September 30, 2025 as compared to the same period in 2024.
Net cash from operating activities of $177.7 million for the nine months ended September 30, 2025.

Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.

"We are continuing to add to a record year with 225% revenue growth, Adjusted EBITDA attributable to Nutex Health of $243.0 million, a 629% increase in gross profit and a record high cash balance of $166.0 million. Our financial performance highlights the strength of the business model with our strong balance sheet positioning us well for our planned growth strategy," stated Jon Bates, Chief Financial Officer of Nutex Health.

"We are very pleased to deliver another successful and profitable quarter. With the audit revisions and related activities behind us, our team is fully focused on driving future growth both within existing operations and through new facilities. Our pipeline remains strong, reflecting continued demand for small hospitals across the country," stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.

For more details on the Company's financial results for the three and nine months ended September 30, 2025, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.

Nutex Health Inc. Regains Nasdaq Compliance

On November 19, 2025 Nutex received a letter from Nasdaq Listing Qualifications confirming that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic reports with the Securities and Exchange Commission.

The letter states that following the Company's filing of its Form 10-Q for the period ended June 30, 2025 on November 18, 2025, Nasdaq has determined that Nutex Health Inc. now complies with the rule and that the matter is closed.

No further action is required by the Company in connection with this matter.

Conference Call on Restated 2024 and First Three Quarters of 2025 Results

The Company will host a conference call on Tuesday, December 2, 2025 at 10:30 a.m. ET to discuss its restated fiscal year 2024 results and its results for the first three quarters of 2025.

Participant Listening: 1-877-407-9208 or 1-201-493-6784

Participant Link: https://callme.viavid.com/viavid/?callme=true&passcode=13746493&h=true&info=company&r=true&B=6  

To access the call, please dial in approximately five minutes before start time. Those who are unable to attend the live conference call may access the recording on the Company's website.

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(In thousands, except share and per share amounts)

September 30,
2025

December 31,
2024

Assets

Current assets:

Cash and cash equivalents

$           166,048

$                  40,640

Restricted short-term investments

—

2,941

Accounts receivable

387,409

232,449

Accounts receivable - related parties

7,353

3,602

Inventories

3,158

2,850

Income tax receivable

12,097

—

Prepaid expenses and other current assets

16,586

9,997

Total current assets

592,651

292,479

Property and equipment, net

82,821

77,933

Operating lease right-of-use assets

27,354

27,872

Financing lease right-of-use assets

225,719

218,889

Intangible assets, net

21,555

15,530

Goodwill, net

13,919

13,919

Deferred tax assets

—

7,987

Other assets

499

711

  Total assets

$           964,518

$                655,320

Liabilities and Equity

Current liabilities:

Accounts payable

$             45,475

$                    9,614

Accounts payable - related parties

4,082

806

Lines of credit

5,304

3,554

Current portion of long-term debt

18,004

14,395

Operating lease liabilities, current portion

2,111

2,080

Financing lease liabilities, current portion

7,108

7,705

Accrued arbitration expenses

64,313

47,742

Accrued income tax expense

—

26,533

Accrued stock-based compensation

11,194

16,356

Accrued expenses and other current liabilities

27,865

25,440

Total current liabilities

185,456

154,225

Long-term debt, net

25,574

22,466

Operating lease liabilities, net

30,423

30,617

Financing lease liabilities, net

270,077

259,479

Deferred tax liabilities

14,955

—

  Total liabilities

526,485

466,787

Commitments and contingencies (Note 10)

Equity:

Common stock, $0.001 par value; 950,000,000 shares authorized; 6,905,262 and 5,511,452 shares
issued and outstanding as of September 30, 2025 and December 31, 2024, respectively

7

6

Additional paid-in capital

615,180

489,409

Accumulated deficit

(298,021)

(356,976)

  Nutex Health Inc. equity

317,166

132,439

Noncontrolling interests

120,867

56,094

  Total equity

438,033

188,533

  Total liabilities and equity

$           964,518

$                655,320

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

Three Months Ended September 30,

Nine  Months Ended September 30,

(In thousands, except share and per share amounts)

2025

2024

2025

2024

Revenue:

Hospital division

$         260,239

$           71,733

$         700,488

$         199,367

Population health management division

7,565

7,062

23,090

22,964

Total revenue

267,804

78,795

723,578

222,331

Operating costs and expenses:

Payroll

38,817

29,848

109,961

85,249

Contract services

53,837

11,657

153,601

32,482

Medical supplies

3,307

3,983

11,920

12,894

Depreciation and amortization

5,003

4,972

15,343

13,691

Other

11,959

6,418

34,610

23,380

Total operating costs and expenses

112,923

56,878

325,435

167,696

Gross profit

154,881

21,917

398,143

54,635

Corporate and other costs:

Stock-based compensation

13,217

1,964

119,606

1,952

Impairment of assets

—

425

—

3,899

Impairment of goodwill

—

—

—

3,197

General and administrative expenses

11,297

9,865

33,830

29,175

Total corporate and other costs

24,514

12,254

153,436

38,223

Operating income

130,367

9,663

244,707

16,412

Interest expense, net

5,452

5,381

17,250

14,880

Loss on warrant liability

—

6,734

—

1,073

Other (income) expense

976

128

8,570

(711)

Income (loss) before taxes

123,939

(2,580)

218,887

1,170

Income tax expense

27,140

4,585

55,138

5,868

Net income (loss)

96,799

(7,165)

163,749

(4,698)

Less: net income attributable to noncontrolling interests

41,364

1,623

104,794

4,819

Net income (loss) attributable to Nutex Health Inc.

$           55,435

$            (8,788)

$           58,955

$            (9,517)

Earnings (loss) per common share

Basic

$                8.27

$              (1.72)

$                9.63

$              (1.91)

Diluted

$                7.76

$              (1.72)

$                8.87

$              (1.91)

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Nine Months Ended September 30,

(In thousands)

2025

2024

Cash flows from operating activities:

Net income

$           163,749

$             (4,698)

Adjustment to reconcile net income to net cash from operating activities:

Depreciation and amortization

15,343

13,691

Loss on warrant liability

—

1,073

Impairment of assets

—

3,899

Impairment of goodwill

—

3,197

Derecognition of goodwill

—

453

Stock-based compensation expense

119,606

1,952

Changes to deferred taxes

22,942

(1,743)

Debt accretion expense

756

805

Changes in operating assets and liabilities:

(Increase)/Decrease in Accounts receivable

(154,960)

(4,253)

(Increase)/Decrease in Accounts receivable - related party

(3,751)

550

(Increase)/Decrease in Inventories

(308)

1,131

(Increase)/Decrease in Income tax receivable

(12,097)

—

(Increase)/Decrease in Prepaid expenses and other current assets

(6,376)

(1,361)

(Increase)/Decrease in Operating right-of-use assets

518

411

Increase/(Decrease) in Accounts payable

36,637

(7,975)

Increase/(Decrease) in Accounts payable - related party

3,276

(39)

Increase/(Decrease) in Operating lease liabilities

(164)

(692)

Increase/(Decrease) in Accrued arbitration expenses

16,571

—

Increase/(Decrease) in Accrued income tax expense

(26,533)

—

Increase/(Decrease) in Accrued expenses and other current liabilities

2,527

16,698

Net cash provided by operating activities

177,736

23,099

Cash flows from investing activities:

Acquisitions of property and equipment

(1,117)

(1,909)

Proceeds from restricted short-term investment

2,941

—

Cash related to sale of business

—

(361)

Cash related to asset acquisition

(1,994)

—

Net cash used in investing activities

(170)

(2,270)

Cash flows from financing activities:

Proceeds from lines of credit

5,043

1,132

Proceeds from notes payable

273

7,015

Repayments of lines of credit

(3,293)

(1,119)

Repayments of notes payable

(8,319)

(8,332)

Repayments of finance leases

(4,004)

(1,924)

Proceeds from common stock issuance, net issuance costs

—

9,202

Proceeds from exercise of warrants

—

801

Members' contributions

316

961

Members' distributions

(42,174)

(3,659)

Net cash provided by (used in) financing activities

(52,158)

4,077

Net increase in cash and cash equivalents

125,408

24,906

Cash and cash equivalents - beginning of the period

40,640

22,002

Cash and cash equivalents - end of the period

$           166,048

$             46,908

Non-GAAP Financial Measures (Unaudited)

EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance.

We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization.

We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for stock-based compensation, certain defined items of expense and any acquisition-related costs and impairments. Interest expense includes interest on lease liabilities, which is a component of total finance lease cost. A reconciliation of net loss to Adjusted EBITDA is included below.

Beginning in the first quarter of 2025, we have updated our presentation of Adjusted EBITDA to separately disclose finance lease payments related to leases under ASC 842. We believe this change provides greater transparency into our operating performance.

Adjusted EBITDA is not intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies. Adjusted EBITDA follows (in thousands):

Three Months Ended September 30,

2025

2024

Reconciliation of net income (loss) attributable to Nutex
Health Inc. to Adjusted EBITDA:

(Updated)

(Prior)

(Updated)

(Prior)

Net income (loss) attributable to Nutex Health Inc.

$           55,435

$           55,435

$            (8,788)

$            (8,788)

Depreciation and amortization

5,003

5,003

4,972

4,972

Interest expense, net

5,452

5,452

5,381

5,381

Income tax expense

27,140

27,140

4,585

4,585

Allocation to noncontrolling interests

(1,243)

(1,243)

(1,808)

(1,808)

EBITDA

91,787

91,787

4,342

4,342

Loss on warrant liability

—

—

6,734

6,734

Impairment of assets

—

—

424

424

Finance lease payments(1)

(6,474)

—

(3,794)

—

Stock-based compensation

13,217

13,217

1,964

1,964

Adjusted EBITDA

$           98,530

$         105,004

$              9,670

$           13,464

Nine Months Ended September 30,

2025

2024

Reconciliation of net income (loss) attributable to Nutex
Health Inc. to Adjusted EBITDA:

(Updated)

(Prior)

(Updated)

(Prior)

Net income (loss) attributable to Nutex Health Inc.

$           58,955

$           58,955

$            (9,517)

$            (9,517)

Depreciation and amortization

15,343

15,343

13,691

13,691

Interest expense, net

17,250

17,250

14,880

14,880

Income tax expense

55,138

55,138

5,868

5,868

Allocation to noncontrolling interests

(3,815)

(3,815)

(4,980)

(4,980)

EBITDA

142,871

142,871

19,942

19,942

Loss on warrant liability

—

—

1,073

1,073

Impairment of assets

—

—

3,898

3,898

Impairment of goodwill

—

—

3,197

3,197

Finance lease payments(1)

(19,512)

—

(13,957)

—

Stock-based compensation

119,606

119,606

1,952

1,952

Adjusted EBITDA

$         242,965

$         262,477

$           16,105

$           30,062

(1)

Finance lease payments consist of cash payments for financing leases under ASC 842, which should be deducted from EBITDA. We believe this change is useful to investors to evaluate the ongoing operating performance of our business.

About Nutex Health Inc.

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.

The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states.

The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups.

Forward-Looking Statements

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result" "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2025 under the heading "Risk Factors" in Part II, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

SOURCE Nutex Health, Inc.

November 19, 2025 4:30 PM EST | Source: SureNano Science Ltd.
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") is pleased to announce it has entered into a non-binding letter of intent (the "LOI") with GlucaPharm Inc. ("GlucaPharm"), to conduct legal, technical and financial due diligence on GlucaPharm and its license to the intellectual property as described below (the "Proposed Transaction"). If the Company elects to proceed following the conclusion of its due diligence, the parties shall negotiate and enter into a definitive binding agreement (the "Definitive Agreement"). The LOI contains both binding and non-binding terms, the former including mutual confidentiality and due diligence access rights, each party bears own expenses and mutual exclusivity of negotiations, and the non-binding terms relating to the substantive terms of the Proposed Transaction share exchange terms.

GlucaPharm is a privately held BC Corporation and holds exclusive rights to develop Syracuse University's GEP-44 GLP-1 pharmaceutical patent protected compound discovery and technology. GEP-44 is a novel compound that addresses diabetes and weight loss, similar to current in-market GLP-1s such as Ozempic, but targeting no-needle administration method and superior tolerability, including reduced side effects most experienced by leading in-market drugs such as nausea and gastrointestinal issues. GEP-44 is a triple antagonist with strong preclinical results, patents filed, academic validation and market exploration underway, poised to transform the treatment of obesity and diabetes worldwide.

Proposed Transaction Overview
The Proposed Transaction is expected to be structured as a share exchange pursuant to which SureNano will acquire 100% of the issued and outstanding common shares in the capital of GlucaPharm through the issuance of an aggregate number of common shares to GlucaPharm shareholders, to be agreed upon subject to completion of Due Diligence, in the capital of SureNano (the "SureNano Shares") upon closing of the Proposed Transaction via a share exchange agreement. Following the closing, it is expected that GlucaPharm shareholders will collectively own under 20% of the issued and outstanding SureNano Shares.

The LOI sets out certain terms and conditions pursuant to which the Proposed Transaction will be completed. The Proposed Transaction remains subject to certain closing conditions, including, without limitation: (a) the completion of customary due diligence; (b) the negotiation and execution of a Definitive Agreement; and (c) the receipt of all required regulatory and third-party approvals and, if applicable, the approval of the GlucaPharm shareholders. There can be no guarantees that the Proposed Transaction will be completed as contemplated, or at all.

Upon the execution of a Definitive Agreement between SureNano and GlucaPharm, the Company will issue a subsequent news release containing the details of the Definitive Agreement and any additional terms of the Proposed Transaction.

Finder's fees may be payable in connection with the Proposed Transaction, all in accordance with the policies of the Canadian Securities Exchange.

SureNano Private Placement
On November 5, 2025, the Company announced its intention to complete a private placement for proceeds of up to $1,250,000 (the "Private Placement") which will consist of the sale of up to 10,000,000 units (each a "Unit") at a price of $0.125 per Unit. Each Unit will be comprised of one common share (a "Common Share") and one Common Share purchase warrant (each a "Warrant"), with each Warrant entitling the holder thereof to acquire one Common Share in the capital of the Company at a price of $0.35 per Common Share for a period of 24 months from the date of issuance. The Warrants will be subject to an acceleration provision, such that if at any time after the date that is four months and one day after the closing, the Company's Shares trade on the Canadian Securities Exchange (the "CSE") at a closing price of $0.50 or greater per Share for a period of ten (10) consecutive trading days, the Company may accelerate the expiry of the Warrants by giving notice to the holders thereof and, in such case, the Warrant will expire on the thirtieth (30th) day after the date of such notice. Refer to SureNano press release dated November 5, 2025, for further details on the Private Placement announcement.

The Company intends to use proceeds of the Private Placement for operating expenses, including legal and audit fees, general working capital, expenses related to exploring new markets for its SureNanoTM surfactant, and to investigate complementary industries including but not limited to GlucaPharm. The negotiations to acquire GlucaPharm and the Private Placement are not interdependent.

About SureNano Science Ltd.:
The business of SureNano Science Ltd. is the sale and distribution of the SureNano™ surfactant, which is a ready-to-mix food grade compound that provides the base for high performance nanoemulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity, and taste. The Company has an exclusive license to distribute the SureNanoTM surfactant within Canada; Oklahoma, USA; and Colorado, USA.

Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of SureNano. Forward-looking information is based on certain key expectations and assumptions made by the management of SureNano. In some cases, you can identify forward-looking statements by the use of words such as “will,” “may,” “would,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “could” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements in this press release include that a) SureNano will acquire 100% of the issued and outstanding common shares in the capital of GlucaPharm, b) the Proposed transaction will be completed, c) the Private Placement will be completed as disclosed, d) finders fees may be paid, e) the Warrants may be accelerated, and f) that GlucaPharm shareholders will hold under 20% of the issued and outstanding shares of SureNano. Although SureNano believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because SureNano can give no assurance that they will prove to be correct.

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275199

SALT LAKE CITY--(BUSINESS WIRE)--KindlyMD, Inc. (NASDAQ: NAKA) (“KindlyMD” or “the Company”), a provider of integrated healthcare services and a Bitcoin treasury company via its subsidiary Nakamoto Holdings, Inc. (“Nakamoto”), today announced its financial and operating results for the quarter ended September 30, 2025, along with an update on its Bitcoin treasury strategy. In May 2025, KindlyMD took a major strategic leap when it announced its merger with Nakamoto and subsequently raised approx.

FARMINGTON, Utah--(BUSINESS WIRE)--PACS announced operating results for the third quarter of 2025. PACS has completed its Restatement of financials and is current with SEC obligations.

Nvidia and xAI said on Wednesday that a large data center facility being built in Saudi Arabia and equipped with hundreds of thousands of Nvidia chips will count Elon Musk's artificial intelligence startup as its first customer.

Musk and Nvidia CEO Jensen Huang were both in attendance at the U.S.-Saudi Investment Forum in Washington, D.C.

The announcement builds on a partnership from May, when Nvidia said it would provide Saudi Arabia's Humain with chips that use 500 megawatts of power. On Wednesday, Humain said the project would include about 600,000 Nvidia graphics processing units.

Humain was launched earlier this year and is owned by the Saudi Public Investment Fund. The plan to build the data center was initially announced when Huang visited Saudi Arabia alongside President Donald Trump.

"Could you imagine, a startup company approximately 0 billion dollars in revenues, now going to build a data center for Elon," Huang said.

The facility is one of the most prominent examples of what Nvidia calls "sovereign AI." The chipmaker has said that nations will increasingly need to build data centers for AI in order to protect national security and their culture. It's also a potentially massive market for Nvidia's pricey AI chips beyond a handful of hyperscalers.

Huang's appearance at an event supported by President Trump is another sign of the administration's focus on AI. Huang has become friendly with the president as Nvidia lobbies to gain licenses to ship future AI chips to China.

When announcing the agreement, Musk, who was a major figure in the early days of the second Trump administration, briefly mixed up the size of the data center, which is measured in megawatts, a unit of power. He joked that plans for a data center that would be 1,000 times larger would have to wait.

"That will be eight bazillion, trillion dollars," Musk joked.

Humain won't just use Nvidia chips. Advanced Micro Devices and Qualcomm will also sell chips and AI systems to Humain. AMD CEO Lisa Su and Qualcomm CEO Cristiano Amon both attended a state dinner on Tuesday to honor Saudi Crown Prince Mohammed bin Salman.

AMD will provide chips that may require as much as 1 gigawatt of power by 2030. The company said the chips that it would provide are its Instinct MI450 GPUs for AI. Cisco will provide additional infrastructure for the data center, AMD said.

Qualcomm will sell Humain its new data center chips that were first revealed in October, called the AI200 and AI250. Humain will deploy 200 megawatts of Qualcomm chips, the company said.

watch now

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Fortinet, Inc. (NASDAQ: FTNT).

Shareholders who purchased shares of FTNT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/fortinet-inc-loss-submission-form/?id=177909&from=3

CLASS PERIOD: November 8, 2024 to August 6, 2025

ALLEGATIONS: According to the filed complaint, defendants made false statements and/or concealed that defendants knew that the refresh cycle would never be as lucrative as they represented, nor could it, because it consisted of old products that were a “small percentage” of the Company’s business. Moreover, defendants misrepresented and concealed that they did not have a clear picture of the true number of FortiGate firewalls that could be upgraded. And while telling investors that the refresh would gain momentum over the course of two years, Fortinet misrepresented and concealed that it had aggressively pushed through roughly half of the refresh in a period of months, by the end of 2Q 2025.

DEADLINE: November 21, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/fortinet-inc-loss-submission-form/?id=177909&from=3

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of FTNT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is November 21, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Molina Healthcare, Inc. (NYSE: MOH).

Shareholders who purchased shares of MOH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/molina-healthcare-inc-loss-submission-form/?id=177907&from=3

CLASS PERIOD: February 5, 2025 to July 23, 2025

ALLEGATIONS: According to the filed complaint, defendants made false statements and/or concealed: (1) material, adverse facts concerning the Company’s “medical cost trend assumptions;” (2) that Molina was experiencing a “dislocation between premium rates and medical cost trend;” (3) that Molina’s near term growth was dependent on a lack of “utilization of behavioral health, pharmacy, and inpatient and outpatient services;” (4) as a result of the foregoing, Molina’s financial guidance for fiscal year 2025 was substantially likely to be cut; and (5) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis Molina's stock price dropped following this news.

DEADLINE: December 2, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/molina-healthcare-inc-loss-submission-form/?id=177907&from=3 

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of MOH during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is December 2, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected] 
Phone: (646) 453-8903

Yann LeCun, known as one of the godfathers of modern artificial intelligence and one of the first AI visionaries to join the company then known as Facebook, is leaving Meta.

LuCun said in a LinkedIn post on Wednesday that he plans to create a startup that specializes in a kind of AI technology that researchers have described as world models, analyzing information beyond web data in order to better represent the physical world and its properties.

"I am creating a startup company to continue the Advanced Machine Intelligence research program (AMI) I have been pursuing over the last several years with colleagues at FAIR, at NYU, and beyond," LeCun wrote. "The goal of the startup is to bring about the next big revolution in AI: systems that understand the physical world, have persistent memory, can reason, and can plan complex action sequences."

Meta will partner with LeCun's startup.

The departure comes at a time of disarray within Meta's AI unit, which was dramatically overhauled this year after the company released the fourth version of its Llama open-source large language model to a disappointing response from developers. That spurred CEO Mark Zuckerberg to spend billions of dollars recruiting top AI talent, including a June $14.5 billion investment in Scale AI to lure the startup's 28-year-old CEO Alexandr Wang, now Meta's new chief AI officer.

LeCun, 65, joined Facebook in 2013 to be director of the FAIR AI research division while maintaining a part-time professorial position at New York University.

At the time, Facebook and Google were heavily recruiting high-level academics like LeCun to spearhead their efforts to produce cutting-edge computer science research that could potentially benefit their core businesses and products.

LeCun, along with other AI luminaries like Yoshua Bengio and Geoffrey Hinton, centered their academic research on a kind of AI technique known as deep learning, which involves the training of enormous software systems called neural networks so they can discover patterns within reams of data. The researchers helped popularize the deep learning approach, and in 2019 won the prestigious Turing Award, presented by the Association for Computing Machinery.

Since then, LeCun's approach to AI development has drifted from the direction taken by Meta and the rest of Silicon Valley.

Meta and other tech companies like OpenAI have spent billions of dollars in developing so-called foundation models, particularly LLMs, as part of their efforts to advance state-of-the-art computing. However, LeCun and other deep-learning experts, have said that these current AI models, while powerful, have a limited understanding of the world, and new computing architectures are needed for researchers to create software that's on par with or surpasses humans on certain tasks, a notion known as artificial general intelligence.

"As I envision it, AMI will have far-ranging applications in many sectors of the economy, some of which overlap with Meta's commercial interests, but many of which do not," LeCun said in the post. "Pursuing the goal of AMI in an independent entity is a way to maximize its broad impact."

Besides Wang, other recent notables that Zuckerberg brought in to revamp Meta's AI unit include former GitHub CEO Nat Friedman, who heads the unit's product team, and ChatGPT co-creator Shengjia Zhao, the group's chief scientist.

In October, Meta laid off 600 employees from its Superintelligence Labs division, including some who were part of the FAIR unit that LeCun helped get off the ground. Those layoffs and other cuts to FAIR over the years, coupled with a new AI leadership team, played a major role in LeCun's decision to leave, according to people familiar with the matter who asked not to be named because they weren't authorized to speak publicly.

Additionally, LeCun rarely interacted with Wang nor TBD Labs unit, which is compromised of many of the headline-grabbing hires Zuckerberg made over the summer. TBD Labs oversees the development of Meta's Llama AI models, which were originally developed within FAIR, the people said.

While LeCun was always a champion of sharing AI research and related technologies to the open-source community, Wang and his team favor a more closed approach amid intense competition from rivals like OpenAI and Google, the people said.

WATCH: Meta is a table pounder here.

NASHVILLE, Tenn.--(BUSINESS WIRE)--Five9 CX Summit – Five9 (Nasdaq: FIVN), provider of the Intelligent CX Platform, today announced the winners of the 2025 New Era of CX Awards during Five9 CX Summit 2025. The awards recognize organizations and partners who are redefining what's possible in customer and employee experience through innovation, AI, and automation. This recognition celebrates those who have achieved measurable business outcomes and demonstrated exceptional creativity in leveraging.

Clarivate Plc (CLVT) Global Technology, Internet, Media & Telecommunications Conference 2025 November 19, 2025 1:20 PM EST

Company Participants

Matti Shem Tov - CEO & Director
Jonathan Collins - Executive VP & CFO

Conference Call Participants

Ashish Sabadra - RBC Capital Markets, Research Division

Presentation

Ashish Sabadra
RBC Capital Markets, Research Division

Sabadra, and I cover information services companies here at RBC. Matti -- we are excited to host Matti, CEO; and Jonathan CFO of Clarivate. Thanks for giving us this opportunity.

Matti Shem Tov
CEO & Director

Yes. Thank you. Happy to be here.

Question-and-Answer Session

Ashish Sabadra
RBC Capital Markets, Research Division

We'll kick off with the #1 question that we are getting across our coverage universe. It's all about GenAI. GenAI, GenAI, GenAI. So GenAI first from the top line, how do you think about -- one of the concerns is disintermediation risk. So can you talk about how proprietary is your data? How deeply embedded are you in your client workflows? And if you can go through all your segments, like all 3 of them at a very high level, talk about why is -- how do you think about GenAI, but also from not only disintermediation risk but also monetization opportunity, how it's going to open up newer ways for you to monetize.

Matti Shem Tov
CEO & Director

Yes. Sure. First of all, thank you for hosting us today here. Definitely, AI is not going to displace Clarivate. In fact, AI is a great opportunity for us because of the unique nature of our proprietary data and I'll talk about it in general and then I'll talk about segment by segment.

Our data is unique, and we are in a very unique position to strive in the era of AI because the foundation of the company

Recommended For You

SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- On November 17, 2025, James Hardie Industries plc (NYSE: JHX) announced the departure of its CFO (Rachel Wilson) who was immediately replaced by outsider Ryan Lada.

This development follows the 34% August 20, 2025 collapse in James Hardie’s share price and the class-action lawsuit filed against it and certain of its executives, alleging Defendants committed securities fraud by misleading investors about inventory levels and customer demand in its crucial North American segment.

Hagens Berman is investigating the alleged claims and urges investors in James Hardie who suffered significant losses to contact the firm now.

Read more about the issue facing JHX investors, Alleged Inventory Deception: Investors Claim James Hardie Concealed Weak Demand.

Class Period: May 20, 2025 – Aug. 18, 2025
Lead Plaintiff Deadline: Dec. 23, 2025
Visit: www.hbsslaw.com/investor-fraud/jhx
Contact the Firm Now: [email protected]
844-916-0895

The James Hardie Industries (JHX) Securities Class Action

James Hardie Industries plc is the dominant producer of fiber cement building materials in the U.S..

The lawsuit, Laborers’ District Council & Contractors’ Pension Fund of Ohio v. James Hardie Industries plc., et al., 25-cv-13018 (N.D. Ill.), filed on behalf of all investors who purchased or acquired James Hardie common stock—which converted from American Depositary Shares on July 1, 2025—between May 20, 2025, and August 18, 2025 (the "Class Period"), seeks damages for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.

The action centers on James Hardie’s North America Fiber Cement segment, which the company states generates about 80% of its total earnings. The plaintiffs allege that despite the company starting to observe significant inventory destocking by its North American channel partners in April and early May 2025, management publicly denied the trend and assured investors of the segment’s sustained strength.

Specifically, the complaint highlights statements made by company executives on or around May 20 and 21, 2025, which it claims falsely represented that customer demand remained robust and expressly denied that inventory destocking was occurring. The plaintiffs contend that these assurances concealed an underlying problem: sales were artificially inflated by “inventory loading by channel partners, with the hallmarks of fraudulent channel stuffing,” rather than genuine, sustainable customer demand.

This alleged deception came to a head on August 19, 2025, when James Hardie belatedly disclosed a sharp decline in performance. The company reported that sales in the North America Fiber Cement division had dropped by 12%, attributing the decline to the very customer destocking it had previously denied, which management now admitted had been discovered "in April through May."

Company CEO and Executive Director Aaron Erter sought to frame the downturn as a “normalization of channel inventories,” but cautioned that the impact was expected to affect sales for at least the next two quarters.

The market’s reaction was severe and swift. Following the disclosure, James Hardie’s common stock dropped by over 34%.

The plaintiffs argue that this precipitous decline—and the significant losses suffered by investors—was a direct result of the defendants’ alleged wrongful acts and omissions during the Class Period. The lawsuit aims to recover damages on behalf of the Class Members who were financially injured by the sudden reversal of the company’s reported financial health.

Hagens Berman’s Investigation on Behalf of Investors

Hagens Berman is actively investigating the alleged claims.

“We want to know if James Hardie’s sales were fueled by unsustainable sales practices and whether senior management was aware of the problem,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in James Hardie and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to frequently asked questions about the James Hardie case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding James Hardie should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Contact:
Reed Kathrein, 844-916-0895

XRP is under renewed pressure as the broader market downturn drags its profitability metrics back to levels last seen during Donald Trump’s November 2024 re-election.

Glassnode data shows that only 58.5% of XRP’s circulating supply is now in profit. That is the weakest reading since late November 2024, when the token hovered around $0.53.

Even at today’s price of roughly $2.15, about 41.5% of all circulating XRP, equating to nearly 26.5 billion tokens, sits at a realized loss.

XRP’s Supply in Profit (Source: Glassnode)According to the firm, the imbalance reflects how much of this year’s trading volume clustered near elevated price zones. That concentration has left late buyers exposed as momentum fades.

According to CryptoSlate’s data, XRP has dropped 12% in the past six months and trades 40% below its July cycle peak of $3.65.

Why is XRP struggling?Notably, derivatives activity has reinforced that cautious sentiment.

According to CoinGlass data, XRP futures open interest has collapsed to about $3.8 billion, down sharply from almost $10 billion earlier this year.

XRP’s Open Interest YTD (Source: CoinGlass)Open interest tracks the value of active futures contracts. As a result, lower levels typically show that speculative demand is weakening and traders are pulling back from directional bets.

This explains why XRP’s price growth has stalled significantly since its post-election spike. Indeed, XRP has traded chiefly sideways in a tight range around $2.10, disappointing traders who expected follow-through above that level.

Apart from that, XRP’s price has struggled significantly because its long-term holders have stepped up their profit-taking.

Glassnode noted that investors who accumulated XRP below $1 ahead of the late-2024 run are now unwinding positions at a breakneck pace.

According to the firm, this cohort profit-realization activity has risen 240% since September, climbing from about $65 million a day to nearly $220 million.

XRP’s Long-Term Holders Profit Taking (Source: Glassnode)Strong fundamentalsDespite the short-term weakness, the token’s underlying fundamentals remain intact.

Earlier this year, Ripple resolved its multi-year dispute with the US Securities and Exchange Commission (SEC) through a settlement following several favorable rulings.

At the same time, Ripple’s recent $500 million raise, strategic acquisitions of Palisade and Hidden Roads, and several partnerships are strengthening the company’s product suite and expanding its global presence.

Market analysts view these developments as supportive of the asset’s long-term positioning because they build out the ecosystem that relies on the token.

Moreover, institutional interest in the digital assets continues to rise.

Several spot XRP ETFs have launched in November 2025, including products from Franklin Templeton, Bitwise, 21Shares, and CoinShares. Notably, Canary Capital’s XRPC ETF has already drawn nearly $278 million in early inflows, according to SoSoValue data.

XRP ETF Daily Inflows (Source: SoSoValue)At the same time, the blockchain analytics platform Santiment noted that XRP remains a major topic across social platforms, with discussions focusing on ETF launches, market volatility, and the token’s positioning relative to Bitcoin, Ethereum, Solana, and Cardano.

Additionally, the firm also flagged recent retail sales as evidence of an imminent price rebound.

XRP Retailers Dumping (Source: Santiment)It noted that wallets holding fewer than 100 XRP have sold 1.38% of their balances since early November. Retail capitulation often precedes rebounds, and analysts are watching the trend as a potential sign of recovery.

Mentioned in this article

On Wednesday, the crypto market coughed up a hefty chunk of value as bitcoin slipped under the $89,000 mark and ethereum dipped below $2,900. While the heavyweights took their hits, plenty of alternative assets face-planted hard enough to make even seasoned holders feel queasy.